Jaguar Health has been granted a patent for methods and compositions to treat congenital diarrheal disorders (CDD) using proanthocyanidin polymer from Croton lechleri. The treatment addresses secretory diarrhea symptoms and improves patient health. GlobalData’s report on Jaguar Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Jaguar Health Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jaguar Health, Cancer treatment biomarkers was a key innovation area identified from patents. Jaguar Health's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11857510B2) discloses a method for treating secretory diarrhea associated with Microvillous Inclusion Disease (MVID) in subjects, particularly human infants requiring parenteral nutrition. The method involves administering a composition containing isolated proanthocyanidin polymer from Croton lechleri, specifically crofelemer, in an aqueous vehicle at a dose of 2 mg/kg to 10 mg/kg per day. This treatment is recommended to be initiated after the subject begins exhibiting symptoms of MVID, ideally within the first month or year of birth.

Furthermore, the patent claims that the subject can be considered treated if there is an improvement in nutritional status or electrolyte balance, along with specific indicators such as a decrease in the number of bowel movements per day, a decrease in watery bowel movements, an improvement in daily abdominal pain or discomfort scores, or an enhancement in daily stool consistency. The method emphasizes the importance of administering the proanthocyanidin polymer composition from Croton lechleri within the specified dosage range multiple times a day to effectively manage secretory diarrhea associated with MVID. This patent provides a novel approach to addressing a specific medical condition in vulnerable populations, highlighting the potential benefits of utilizing natural compounds for therapeutic purposes.

To know more about GlobalData’s detailed insights on Jaguar Health, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies